There was an inadvertent public disclosure of aggregate data that was partially derived from pre-released information,” a ...

Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a ...

The 1984 Chevrolet Corvette did more than usher in a new generation of America’s sports car, it dragged the dashboard into the computer age. Instead of analog needles and chrome bezels, drivers stared ...

The referee appointed to the case, Third Judicial Circuit Judge Gregory Stuart Parker, has requested a Jan. 15, 2026, deadline to issue a report on the case. It will ultimately be up to Florida ...

Every day, Bridget Dunlap steps outside her Rainey Street bar hoping to feel an energy in the air that says business might finally pick up again. For the past few years, construction crews have mostly ...

The ongoing shutdown of major pieces of the federal government has meant missed paychecks for federal workers, no new loans from the Small Business Administration, no giant panda cam from the National ...

Fast-growing tech giant AppLovin is facing fresh regulatory heat over its handling of consumer data –including potential investigations by multiple state attorneys general, The Post has learned. The ...

For one week this summer, Taylor and her roommate wore GoPro cameras strapped to their foreheads as they painted, sculpted, and did household chores. They were training an AI vision model, carefully ...

CrowdStrike Holdings Inc.’s Enterprise Graph solution is the company’s latest defense against cyberattacks fueled by agentic artificial intelligence. The innovation is part of the company’s new ...

ON SEPTEMBER 10th Charlie Kirk, a right-wing activist, was shot dead while speaking at a university in Utah. Although a suspect is in custody, the motive of the killer is still unknown. President ...

Another fairly straightforward day for the bond market with friendly econ data and a strong 10yr Treasury auction both helping push yields lower. If it seems like the size of the miss in the PPI data ...

Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered PD-1xVEGF drug showed consistent benefit between China and Western populations ...